Albert Beckers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/646395/publications.pdf

Version: 2024-02-01

222	13,296	22548	29333
papers	citations	61 h-index	108 g-index

229	229	229	6578
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa. Endocrine Connections, 2022, 11, .	0.8	2
2	Pituitary <scp>MRI</scp> in Cushing's disease â€•an update. Journal of Neuroendocrinology, 2022, 34, e13123.	1.2	24
3	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
4	Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism. American Journal of Human Genetics, 2022, 109, 553-570.	2.6	18
5	Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptorâ€“Interacting Proteinâ€“mutated Pediatric Somatotropinoma. AACE Clinical Case Reports, 2022, 8, 119-123.	0.4	2
6	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	1.8	7
7	Medical management of pituitary gigantism and acromegaly. , 2021, , 245-257.		0
8	A Hard Look at Cardiac Safety with Dopamine Agonists in Endocrinology. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2452-e2454.	1.8	2
9	GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of G s and G q/11. FASEB Journal, 2021, 35, .	0.2	1
10	Gigantism: clinical diagnosis and description. , 2021, , 39-52.		0
11	History of the identification of gigantism and acromegaly. , 2021, , 1-16.		0
12	Acromegaly: clinical description and diagnosis. , 2021, , 53-78.		0
13	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. Endocrinology, 2021, , 291-311.	0.1	0
14	Thyroid cancer in the Democratic Republic of the Congo: Frequency and risk factors. Annales D'Endocrinologie, 2021, 82, 606-612.	0.6	3
15	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. European Journal of Endocrinology, 2021, 185, 863-873.	1.9	12
16	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
17	Acromegaly in the setting of Tatton-Brown-Rahman Syndrome. Pituitary, 2020, 23, 167-170.	1.6	5
18	Long-term remission of disseminated parathyroid cancer following immunotherapy. Endocrine, 2020, 67, 204-208.	1.1	15

#	Article	IF	Citations
19	Association between mixture of persistent organic pollutants and thyroid pathologies in a Belgian population. Environmental Research, 2020, 181, 108922.	3.7	12
20	Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series. Annales D'Endocrinologie, 2020, 81, 482-486.	0.6	1
21	GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nature Communications, 2020, 11, 4752.	5.8	31
22	<scp>miR</scp>â€34a is upregulated in <scp>AIP</scp>â€mutated somatotropinomas and promotes octreotide resistance. International Journal of Cancer, 2020, 147, 3523-3538.	2.3	25
23	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	2.6	183
24	Neuroimaging of aggressive pituitary tumors. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 235-242.	2.6	6
25	The Epidemiology of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 2020, 49, 347-355.	1.2	137
26	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	1.8	26
27	Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview. Journal of Clinical Medicine, 2020, 9, 2003.	1.0	8
28	Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. Hormone and Metabolic Research, 2020, 52, 784-787.	0.7	9
29	Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. Hormone and Metabolic Research, 2020, 52, 553-561.	0.7	17
30	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA). Endocrine-Related Cancer, 2020, 27, T77-T86.	1.6	11
31	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis. Endocrine-Related Cancer, 2020, 27, T87-T97.	1.6	12
32	Shrinkage of pituitary adenomas with pasireotide. Lancet Diabetes and Endocrinology,the, 2019, 7, 509.	5.5	3
33	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. Endocrinology, 2019, , 1-21.	0.1	0
34	Genetic Testing in Pituitary Adenomas: What, How, and In Whom?. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2019, 66, 71-73.	0.1	0
35	Epidemiology and Management Challenges in Prolactinomas. Neuroendocrinology, 2019, 109, 20-27.	1.2	69
36	Genetic Testing in Pituitary Adenomas: What, How, and In Whom?. Endocrinologia, Diabetes Y NutriciÃ“n, 2019, 66, 71-73.	0.1	1

#	Article	IF	Citations
37	AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocrine Connections, 2019, 8, 367-377.	0.8	44
38	AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. Endocrine Connections, 2019, 8, 338-348.	0.8	26
39	Compound heterozygous mutations in the luteinizing hormone receptor signal peptide causing 46,XY disorder of sex development. European Journal of Endocrinology, 2019, 181, K11-K20.	1.9	7
40	Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. European Journal of Endocrinology, 2019, 181, K21-K27.	1.9	39
41	Somatic and germline mutations in the pathogenesis of pituitary adenomas. European Journal of Endocrinology, 2019, 181, R235-R254.	1.9	33
42	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. Endocrinology, 2019, , 1-21.	0.1	0
43	Pituitary Tumors Associated With Multiple Endocrine Neoplasia Syndromes. , 2019, , 642-647.		1
44	Prognostic Factors: Molecular Pathway â€“ Tumour Suppressor Gene (MEN1). , 2018, , 135-148.		0
45	Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocrine-Related Cancer, 2018, 25, L37-L42.	1.6	57
46	Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51â€Case Cohort Study. World Journal of Surgery, 2018, 42, 143-152.	0.8	27
47	Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients. Archives of Endocrinology and Metabolism, 2018, 62, 609-614.	0.3	26
48	The causes and consequences of pituitary gigantism. Nature Reviews Endocrinology, 2018, 14, 705-720.	4.3	57
49	Resistant Paediatric Somatotropinomas due to <i>AIP</i> Mutations: Role of Pegvisomant. Hormone Research in Paediatrics, 2018, 90, 196-202.	0.8	25
50	Tumor cells may circulate in medullary thyroid cancer patients independently of serum calcitonin. Endocrine-Related Cancer, 2018, 25, L59-L63.	1.6	4
51	Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARÎ±) in Non-Somatotroph Pituitary Tumours and the Effects of PPARÎ± Agonists on MMQ Cells. Hormone and Metabolic Research, 2018, 50, 640-647.	0.7	3
52	Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism. Endocrine-Related Cancer, 2017, 24, L17-L20.	1.6	19
53	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. European Journal of Endocrinology, 2017, 176, 323-328.	1.9	27
54	T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary, 2017, 20, 116-120.	1.6	43

#	Article	IF	Citations
55	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	1.9	133
56	How to recognize Cowden syndrome: A novel PTEN mutation description. Annales D'Endocrinologie, 2017, 78, 188-190.	0.6	6
57	Adipsic diabetes insipidus revealing a bifocal intracranial germinoma. Annales D'Endocrinologie, 2017, 78, 141-145.	0.6	5
58	AIP mutations and gigantism. Annales D'Endocrinologie, 2017, 78, 123-130.	0.6	11
59	X-LAG: How did they grow so tall?. Annales D'Endocrinologie, 2017, 78, 131-136.	0.6	9
60	From the shortest to the tallest. Annales D'Endocrinologie, 2017, 78, 75-76.	0.6	0
61	Cabergoline for Cushingâ€™s disease: a large retrospective multicenter study. European Journal of Endocrinology, 2017, 176, 305-314.	1.9	77
62	The role of AIP mutations in pituitary adenomas: 10 years on. Endocrine, 2017, 55, 333-335.	1.1	12
63	Acromegaly at diagnosis in 3173 patients from the LiÃ¨ge Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
64	Genetics of Pituitary Tumor Syndromes. , 2017, , 619-630.		5
65	Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine, 2017, 55, 239-245.	1.1	23
66	Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor. Archives of Endocrinology and Metabolism, 2017, 61, 506-509.	0.3	10
67	Comment on â€œHypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone Î²-subunit geneâ€. Korean Journal of Internal Medicine, 2017, 32, 566-567.	0.7	2
68	Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.2	8
69	Functioning Pituitary Adenomas. , 2016, , 79-91.		0
70	Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation. Endocrine-Related Cancer, 2016, 23, 391-397.	1.6	29
71	MANAGEMENT OF ENDOCRINE DISEASE: Pituitary â€˜incidentalomaâ€™: neuroradiological assessment and differential diagnosis. European Journal of Endocrinology, 2016, 175, R171-R184.	1.9	60
72	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. Hormone and Metabolic Research, 2016, 48, 389-393.	0.7	18

#	Article	IF	Citations
73	Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARÎ±) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and inÂvitro effects of fenofibrate in GH3 cells. Molecular and Cellular Endocrinology, 2016, 426, 61-72.	1.6	2
74	A vital region for human glycoprotein hormone trafficking revealed by an LHB mutation. Journal of Endocrinology, 2016, 231, 197-207.	1.2	34
75	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 2016, 23, 871-881.	1.6	82
76	Screening for genetic causes of growth hormone hypersecretion. Growth Hormone and IGF Research, 2016, 30-31, 52-57.	0.5	20
77	Advances in diagnosis and management of familial pituitary adenomas. International Journal of Endocrine Oncology, 2016, 3, 313-323.	0.4	0
78	Characterization of GPR101 transcript structure and expression patterns. Journal of Molecular Endocrinology, 2016, 57, 97-111.	1.1	34
79	Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. Pituitary, 2016, 19, 507-514.	1.6	27
80	Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine, 2016, 51, 236-244.	1.1	45
81	Screening for GPR101 defects in pediatric pituitary corticotropinomas. Endocrine-Related Cancer, 2016, 23, 357-365.	1.6	30
82	GHRH excess and blockade in X-LAG syndrome. Endocrine-Related Cancer, 2016, 23, 161-170.	1.6	55
83	Persistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease. Gynecological Endocrinology, 2016, 32, 439-441.	0.7	6
84	High prevalence of autoimmune thyroid diseases in patients with prolactinomas: A cross-sectional retrospective study in a single tertiary referral centre. Annales D'Endocrinologie, 2016, 77, 37-42.	0.6	11
85	Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocrine-Related Cancer, 2016, 23, 221-233.	1.6	75
86	Pituitary gigantism: Causes and clinical characteristics. Annales D'Endocrinologie, 2015, 76, 643-649.	0.6	21
87	Familial Isolated Pituitary Adenomas (FIPA) and Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene. Endocrinology and Metabolism Clinics of North America, 2015, 44, 19-25.	1.2	49
88	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114
89	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	1.6	78
90	A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1. European Journal of Endocrinology, 2015, 172, K27-K36.	1.9	18

#	Article	IF	Citations
91	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	1.6	155
92	Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology, 2015, 57, 679-684.	1.1	28
93	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 2015, 22, 353-367.	1.6	151
94	Parathyroid carcinoma: Challenges in diagnosis and treatment. Annales D'Endocrinologie, 2015, 76, 169-177.	0.6	69
95	The acromegalic voice of Tango: Don Edmundo Rivero. Journal of Endocrinological Investigation, 2015, 38, 1023-1024.	1.8	2
96	Gigantism Remains a Clinical Challenge. Archives of Iranian Medicine, 2015, 18, 871.	0.2	0
97	Challenges and controversies in the treatment of prolactinomas. Expert Review of Endocrinology and Metabolism, 2014, 9, 593-604.	1.2	2
98	Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. New England Journal of Medicine, 2014, 371, 2363-2374.	13.9	292
99	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, openâ€label, phase I study. Journal of Clinical Pharmacology, 2014, 54, 1308-1317.	1.0	28
100	Reproduction, Smell, and Neurodevelopmental Disorders: Genetic Defects in Different Hypogonadotropic Hypogonadal Syndromes. Frontiers in Endocrinology, 2014, 5, 109.	1.5	111
101	A bittersweet symphony. Endocrine-Related Cancer, 2014, 21, C7-C9.	1.6	0
102	Deletion of exons 1â€“3 of the MEN1 gene in a large Italian family causes the loss of menin expression. Familial Cancer, 2014, 13, 273-80.	0.9	8
103	The Third/Second Generation PTH Assay Ratio as a Marker for Parathyroid Carcinoma: Evaluation Using an Automated Platform. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E453-E457.	1.8	36
104	McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2029-E2038.	1.8	55
105	A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140048.	0.2	6
106	Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene. Endocrine Reviews, 2013, 34, 239-277.	8.9	289
107	Means, Motive, and Opportunity: SDH Mutations Are Suspects in Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2274-2276.	1.8	7
108	Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. European Journal of Endocrinology, 2013, 168, 533-541.	1.9	146

#	Article	IF	Citations
109	Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe dâ€™Ã©tude des Tumeurs Endocrines (GTE) cohort study. Human Molecular Genetics, 2013, 22, 1940-1948.	1.4	81
110	Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocrine-Related Cancer, 2013, 20, 753-766.	1.6	50
111	Familial Pituitary Adenomas: An Overview. , 2013, , 103-112.		2
112	The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas. , 2013, , 189-201.		0
113	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 651-662.	1.9	173
114	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocrine-Related Cancer, 2012, 19, 233-241.	1.6	72
115	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 887-887.	1.9	2
116	Professor Rolf C. Gaillard. Pituitary, 2012, 15, 465-465.	1.6	0
117	The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly. Annales D'Endocrinologie, 2012, 73, 190-201.	0.6	22
118	Clinical and genetic aspects of familial isolated pituitary adenomas. Clinics, 2012, 67, 37-41.	0.6	14
119	Overview of genetic testing in patients with pituitary adenomas. Annales D'Endocrinologie, 2012, 73, 62-64.	0.6	9
120	Acromegaly and sleep apnea: Cephalometric evaluations. Annales D'Endocrinologie, 2011, 72, 211-217.	0.6	5
121	Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 894-904.	1.8	452
122	Human anti-animal antibodies interference in the Siemens Immulite chemiluminescent insulin immuno-assay: About one case. Clinica Chimica Acta, 2011, 412, 668-669.	0.5	7
123	Familial Pituitary Tumor Syndromes. Endocrine Practice, 2011, 17, 41-46.	1.1	27
124	Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis. European Journal of Endocrinology, 2011, 165, 353-358.	1.9	4
125	Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'Ã©tude des Tumeurs Endocrines. European Journal of Endocrinology, 2011, 165, 97-105.	1.9	101
126	Hyperplasiaâ€“adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocrine-Related Cancer, 2011, 18, 347-356.	1.6	66

#	Article	IF	Citations
127	Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Expert Review of Endocrinology and Metabolism, 2011, 6, 195-214.	1.2	22
128	High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology, 2011, 165, 509-515.	1.9	152
129	Genetic Causes of Familial Pituitary Adenomas. , 2011, , 137-150.		0
130	What to do with a pituitary incidentaloma?. Expert Review of Endocrinology and Metabolism, 2011, 6, 505-507.	1.2	0
131	Management of acromegaly. F1000 Medicine Reports, 2010, 2, 54.	2.9	4
132	Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe dâ€™Etude des Tumeurs Endocrines) Cohort Study Among 758ÂPatients. World Journal of Surgery, 2010, 34, 249-255.	0.8	293
133	Higher prevalence of clinically relevant pituitary adenomas confirmed. Clinical Endocrinology, 2010, 72, 290-291.	1.2	20
134	The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clinical Genetics, 2010, 78, 457-463.	1.0	182
135	Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 761-767.	1.3	21
136	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	1.8	323
137	Functioning Pituitary Adenomas. , 2010, , 55-65.		0
138	Genetics of Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 6-10.	1.2	22
139	The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3745-3749.	1.8	57
140	Familial pituitary adenomas. Annales D'Endocrinologie, 2010, 71, 479-485.	0.6	23
141	Medical Treatment in Cushingâ€™s Syndrome: Dopamine Agonists and Cabergoline. Neuroendocrinology, 2010, 92, 116-119.	1.2	32
142	The genetics of pituitary adenomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 461-476.	2.2	81
143	Genetic Factors in the Development of Pituitary Adenomas. Endocrine Development, 2009, 17, 121-133.	1.3	13
144	Update on Familial Pituitary Tumors: from Multiple Endocrine Neoplasia Type 1 to Familial Isolated Pituitary Adenoma. Hormone Research in Paediatrics, 2009, 71, 105-111.	0.8	15

#	Article	IF	Citations
145	Genetic, Molecular and Clinical Features of Familial Isolated Pituitary Adenomas. Hormone Research in Paediatrics, 2009, 71, 116-122.	0.8	27
146	Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. European Journal of Endocrinology, 2009, 161, 799-804.	1.9	45
147	Testicular Effects of Isolated Luteinizing Hormone Deficiency and Reversal by Long-Term Human Chorionic Gonadotropin Treatment. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3-4.	1.8	21
148	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer, 2009, 16, 1029-1043.	1.6	134
149	Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. International Journal of Cancer, 2009, 125, 2122-2126.	2.3	55
150	Familial pituitary adenomas. Journal of Internal Medicine, 2009, 266, 5-18.	2.7	44
151	The epidemiology and genetics of pituitary adenomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 543-554.	2.2	161
152	French consensus on the management of acromegaly. Annales D'Endocrinologie, 2009, 70, 92-106.	0.6	27
153	Pituitary adenomas in young patients: when should we consider a genetic predisposition?. Expert Review of Endocrinology and Metabolism, 2009, 4, 529-531.	1.2	4
154	De la gÃ©nÃ©tique des adÃ©nomes hypophysaires familiaux. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 1557-1571.	0.0	1
155	Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 177-184.	1.2	17
156	Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox. Annales D'Endocrinologie, 2008, 69, 47-52.	0.6	1
157	Current and future perspectives on recombinant growth hormone for the treatment of obesity. Expert Review of Endocrinology and Metabolism, 2008, 3, 75-90.	1.2	0
158	Cabergoline and the risk of valvular lesions in endocrine disease.. European Journal of Endocrinology, 2008, 159, 1-5.	1.9	131
159	Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2975-2977.	1.8	20
160	Characteristics of familial isolated pituitary adenomas. Expert Review of Endocrinology and Metabolism, 2007, 2, 725-733.	1.2	3
161	Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1952-1955.	1.8	132
162	The Epidemiology and Management of Pituitary Incidentalomas. Hormone Research in Paediatrics, 2007, 68, 195-198.	0.8	29

#	Article	IF	Citations
163	Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 135, 139-140.	0.5	11
164	Classical pituitary tumour apoplexy: Clinical features, management and outcomes in a series of 24 patients. Clinical Neurology and Neurosurgery, 2007, 109, 63-70.	0.6	166
165	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1891-1896.	1.8	283
166	Pseudomalabsorption ofÂthyroid hormones: case report andÂreview ofÂtheÂliterature. Annales D'Endocrinologie, 2007, 68, 460-463.	0.6	15
167	GsÎ± overexpression and loss of GsÎ± imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. International Journal of Cancer, 2007, 121, 1245-1252.	2.3	38
168	The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology, 2007, 157, 371-382.	1.9	160
169	Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. European Journal of Endocrinology, 2007, 157, 383-391.	1.9	84
170	Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 12-13.	2.9	0
171	High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Lieì€ge, Belgium. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4769-4775.	1.8	904
172	Clinical Characterization of Familial Isolated Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3316-3323.	1.8	217
173	Somatostatin Analogs in the Gastrointestinal Tract. , 2006, , 1131-1138.		1
174	Treatment of Pituitary Tumors: Somatostatin. Endocrine, 2005, 28, 093-100.	2.2	13
175	Tensegrity and type 1 dermal dendrocytes in acromegaly. European Journal of Clinical Investigation, 2005, 35, 133-139.	1.7	19
176	The Epidemiology of Prolactinomas. Pituitary, 2005, 8, 3-6.	1.6	247
177	Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology, 2005, 152, 61-66.	1.9	148
178	Clinical and Genetic Features of Familial Pituitary Adenomas. Hormone and Metabolic Research, 2005, 37, 347-354.	0.7	36
179	Octreotide (Long-Acting Release Formulation) Treatment in Patients with Gravesâ€™ Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 841-848.	1.8	78
180	The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology, 2005, 152, 645-654.	1.9	248

#	Article	IF	Citations
181	Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3413-3420.	1.8	113
182	The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomasin Vitro. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1577-1585.	1.8	178
183	Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5308-5313.	1.8	89
184	Hypogonadism in a Patient with a Mutation in the Luteinizing Hormone Beta-Subunit Gene. New England Journal of Medicine, 2004, 351, 2619-2625.	13.9	117
185	Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. European Journal of Endocrinology, 2004, 150, 431-437.	1.9	22
186	Lanreotide Autogel?? for Acromegaly. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 77-81.	1.8	20
187	The treatment of sporadic versus MEN1-related pituitary adenomas. Journal of Internal Medicine, 2003, 253, 599-605.	2.7	68
188	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clinical Endocrinology, 2003, 58, 572-580.	1.2	19
189	Association of acute leukemia and autoimmune polyendocrine syndrome in two kindreds. Leukemia, 2003, 17, 1912-1914.	3.3	2
190	Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 99-104.	1.8	167
191	Skin Tensile Properties in Patients Treated for Acromegaly. Dermatology, 2002, 204, 325-329.	0.9	23
192	Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 457-465.	1.8	413
193	Familial colloid cyst of the third ventricle: neuroendocrinological follow-up and review of the literature. Clinical Neurology and Neurosurgery, 2002, 104, 367-370.	0.6	20
194	The Effects of Growth Hormone Replacement Therapy on Bone Metabolism in Adult-Onset Growth Hormone Deficiency: A 2-Year Open Randomized Controlled Multicenter Trial. Journal of Bone and Mineral Research, 2002, 17, 1081-1094.	3.1	78
195	Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 457-465.	1.8	126
196	Familial acromegaly: case report and review of the literature. Pituitary, 1999, 1, 273-277.	1.6	56
197	Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. , 1999, 13, 54-60.		82
198	Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2518-2522.	1.8	399

#	Article	IF	Citations
199	Comparative densitometric study of iliac crest and scapula bone in relation to osseous integrated dental implants in microvascular mandibular reconstruction. Journal of Cranio-Maxillo-Facial Surgery, 1998, 26, 75-83.	0.7	40
200	The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency. Pharmacoeconomics, 1998, 14, 395-403.	1.7	31
201	Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 374-378.	1.8	337
202	Mutation Analysis of the MEN1 Gene in Multiple Endocrine Neoplasia Type 1, Familial Acromegaly and Familial Isolated Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2621-2626.	1.8	125
203	125I-Tyr0-hCRH Labelling characteristics of corticotropin-releasing hormone receptors: differences between normal and adenomatous corticotrophs. Neurochemistry International, 1997, 30, 291-297.	1.9	11
204	Two years of replacement therapy in adults with growth hormone deficiency. Clinical Endocrinology, 1997, 47, 485-494.	1.2	78
205	Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3771-3776.	1.8	43
206	Presurgical octreotide: Treatment in acromegaly. Metabolism: Clinical and Experimental, 1996, 45, 72-74.	1.5	72
207	The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman. Fertility and Sterility, 1995, 64, 969-971.	0.5	4
208	Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible causeâ€“effect relationship. European Journal of Endocrinology, 1994, 131, 355-358.	1.9	38
209	Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1498-1502.	1.8	26
210	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. European Journal of Endocrinology, 1993, 129, 284-290.	1.9	10
211	Light and Electron Microscopic Immunolocalization of Bovine Pregnancy-Associated Glycoprotein in the Bovine Placentome1. Biology of Reproduction, 1992, 46, 623-629.	1.2	82
212	Diagnosis of primary thyrotrophin-secreting microadenoma by 1.5 T MR. European Journal of Radiology, 1992, 14, 18-21.	1.2	8
213	The association of astrocytoma and pituitary adenoma in a patient with alcaptonuria. Journal of the Neurological Sciences, 1992, 108, 32-34.	0.3	5
214	Presurgical octreotide treatment in acromegaly. Metabolism: Clinical and Experimental, 1992, 41, 51-58.	1.5	91
215	Contrast behavior between microadenoma and normal pituitary gland after gadolinium injection as a function of time at 1.5 T. Neuroradiology, 1992, 34, 184-189.	1.1	10
216	Acute effects of Parlodel-LARÂ® and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma. Journal of Endocrinological Investigation, 1991, 14, 135-138.	1.8	9

#	Article	IF	Citations
217	Effect of treatment with octreotide on the morphology of growth hormoneâ€"secreting pituitary adenomas: Study of 24 cases. Endocrine Pathology, 1991, 2, 123-131.	5.2	13
218	Immunocytochemical Evidence for Production of Luteinizing Hormone and Follicle-Stimulating Hormone in Separate Cells in the Bovine. Biology of Reproduction, 1991, 45, 788-796.	1.2	18
219	Thyrotropin-Secreting Pituitary Adenomas: Report of Seven Cases. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 477-483.	1.8	95
220	Placental and Pituitary Growth Hormone Secretion during Pregnancy in Acromegalic Women. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 725-731.	1.8	94
221	Cyclical Cushingâ€™s disease and its successful control under sodium valproate. Journal of Endocrinological Investigation, 1990, 13, 923-929.	1.8	40
222	Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. , 0, .		104